Literature DB >> 26430763

Oscillatory Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease.

Sarah Svenningsen1,2, Gregory A Paulin1,2, Khadija Sheikh1,2, Fumin Guo1,3, Aasim Hasany1, Miranda Kirby1,2, Roya Etemad Rezai4, David G McCormack5, Grace Parraga1,2,3,4.   

Abstract

Evidence-based guidance for the use of airway clearance techniques (ACT) in chronic obstructive pulmonary disease (COPD) is lacking in-part because well-established measurements of pulmonary function such as the forced expiratory volume in 1s (FEV1) are relatively insensitive to ACT. The objective of this crossover study was to evaluate daily use of an oscillatory positive expiratory pressure (oPEP) device for 21-28 days in COPD patients who were self-identified as sputum-producers or non-sputum-producers. COPD volunteers provided written informed consent to daily oPEP use in a randomized crossover fashion. Participants completed baseline, crossover and study-end pulmonary function tests, St. George's Respiratory Questionnaire (SGRQ), Patient Evaluation Questionnaire (PEQ), Six-Minute Walk Test and (3)He magnetic resonance imaging (MRI) for the measurement of ventilation abnormalities using the ventilation defect percent (VDP). Fourteen COPD patients, self-identified as sputum-producers and 13 COPD-non-sputum-producers completed the study. Post-oPEP, the PEQ-ease-bringing-up-sputum was improved for sputum-producers (p = 0.005) and non-sputum-producers (p = 0.04), the magnitude of which was greater for sputum-producers (p = 0.03). There were significant post-oPEP improvements for sputum-producers only for FVC (p = 0.01), 6MWD (p = 0.04), SGRQ total score (p = 0.01) as well as PEQ-patient-global-assessment (p = 0.02). Clinically relevant post-oPEP improvements for PEQ-ease-bringing-up-sputum/PEQ-patient-global-assessment/SGRQ/VDP were observed in 8/7/9/6 of 14 sputum-producers and 2/0/3/3 of 13 non-sputum-producers. The post-oPEP change in (3)He MRI VDP was related to the change in PEQ-ease-bringing-up-sputum (r = 0.65, p = 0.0004) and FEV1 (r = -0.50, p = 0.009). In COPD patients with chronic sputum production, PEQ and SGRQ scores, FVC and 6MWD improved post-oPEP. FEV1 and PEQ-ease-bringing-up-sputum improvements were related to improved ventilation providing mechanistic evidence to support oPEP use in COPD. Clinical Trials # NCT02282189 and NCT02282202.

Entities:  

Keywords:  airway clearance; chronic bronchitis; pulmonary ventilation; sputum

Mesh:

Year:  2015        PMID: 26430763     DOI: 10.3109/15412555.2015.1043523

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  10 in total

1.  Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of COPD exacerbations.

Authors:  Shoghag Khoudigian-Sinani; Stacey Kowal; Jason A Suggett; Dominic P Coppolo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-10-19

2.  Safety and effectiveness of the high-frequency chest wall oscillation vs intrapulmonary percussive ventilation in patients with severe COPD.

Authors:  Antonello Nicolini; Bruna Grecchi; Maura Ferrari-Bravo; Cornelius Barlascini
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-16

3.  A Functional Respiratory Imaging Approach to the Effect of an Oscillating Positive Expiratory Pressure Device in Chronic Obstructive Pulmonary Disease.

Authors:  Glenn Leemans; Dennis Belmans; Cedric Van Holsbeke; Vladimir Kushnarev; Jason Sugget; Kris Ides; Dirk Vissers; Wilfried De Backer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-04

4.  Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada.

Authors:  Nguyen Xuan Thanh; Philip Jacobs; Jason Suggett; Andrew McIvor; Alan Kaplan
Journal:  Can Respir J       Date:  2019-01-10       Impact factor: 2.409

5.  A Real-World Evidence Study Assessing the Impact of Adding the Aerobika Oscillating Positive Expiratory Pressure Device to Standard of Care Upon Healthcare Resource Utilization and Costs in Post-Operative Patients.

Authors:  Chakkarin Burudpakdee; Aimee M Near; Huan Huang; Dominic Coppolo; Vladimir Kushnarev; Jason Suggett
Journal:  Pulm Ther       Date:  2018-05-16

6.  Role of the active cycle of breathing technique combined with phonophoresis for the treatment of patients with chronic obstructive pulmonary disease (COPD): study protocol for a preliminary randomized controlled trial.

Authors:  M D Shen; L R Guo; Y W Li; R T Gao; X Sui; Z Du; L Q Xu; H Y Shi; Y Y Ni; X Zhang; Y Pang; W Zhang; T Z Yu; F Li
Journal:  Trials       Date:  2021-03-23       Impact factor: 2.279

7.  4-week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial.

Authors:  Galit Livnat; Naama Yaari; Nili Stein; Lea Bentur; Moneera Hanna; Maya Harel; Yochai Adir; Michal Shteinberg
Journal:  ERJ Open Res       Date:  2021-11-08

Review 8.  Non-Pharmaceutical Techniques for Obstructive Airway Clearance Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review.

Authors:  Dominic P Coppolo; Judy Schloss; Jason A Suggett; Jolyon P Mitchell
Journal:  Pulm Ther       Date:  2021-12-03

9.  Adjuncts for sputum clearance in COPD: clinical consensus versus actual use.

Authors:  Ruth Barker; Anthony A Laverty; Nicholas S Hopkinson
Journal:  BMJ Open Respir Res       Date:  2017-07-29

10.  Impact of Oscillating Positive Expiratory Pressure Device Use on Post-Discharge Hospitalizations: A Retrospective Cohort Study Comparing Patients with COPD or Chronic Bronchitis Using the Aerobika® and Acapella® Devices.

Authors:  Jenny Tse; Keiko Wada; Yi Wang; Dominic Coppolo; Vladimir Kushnarev; Jason Suggett
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.